Core Viewpoint - 港通医疗 (301515) experienced a decline in stock price, closing at 21.46 yuan on November 26, 2025, down 1.47% from the previous day [1] Financial Performance - For the first three quarters of 2025, 港通医疗 reported a main revenue of 344 million yuan, a year-on-year decrease of 30.06% [3] - The net profit attributable to shareholders was -10.21 million yuan, a year-on-year decline of 150.92% [3] - The third quarter of 2025 saw a single-quarter main revenue of 79.12 million yuan, an increase of 42.81% year-on-year [3] - The third quarter net profit attributable to shareholders was -1.80 million yuan, a year-on-year decrease of 138.94% [3] - The company reported a gross margin of 22.45% [3] Market Position - 港通医疗's total market capitalization is 2.146 billion yuan, significantly lower than the industry average of 10.995 billion yuan [3] - The company ranks 119th in total market capitalization and 124th in net profit within the medical device industry [3] - The price-to-earnings ratio (P/E) is -157.66, compared to the industry average of 54.59, indicating a poor profitability outlook [3] - The company has a net asset of 1.217 billion yuan, ranking 99th in the industry [3] Capital Flow - On November 26, 2025, the net outflow of main funds was 176,400 yuan, accounting for 0.74% of the total transaction amount [1][2] - Retail investors saw a net outflow of 93,800 yuan, representing 0.39% of the total transaction amount [1][2] - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net inflows and outflows from different investor categories [2]
股票行情快报：港通医疗（301515）11月26日主力资金净卖出17.64万元